| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 08/09/2001 | WO2000073324A9 Modulation of gene expression in gastrointestinal inflammation |
| 08/09/2001 | WO2000070046A9 Secreted polypeptides and corresponding polynucleotides |
| 08/09/2001 | WO2000069257A3 Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
| 08/09/2001 | WO2000066094A3 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents |
| 08/09/2001 | WO2000063351A3 Carbohydrate-modifying enzymes |
| 08/09/2001 | WO2000062813A3 Cationic peg-lipids and methods of use |
| 08/09/2001 | WO2000059878A3 INHIBITORS OF LFA-1 BINDING TO ICAMs AND USES THEREOF |
| 08/09/2001 | WO2000057862A3 Use of gaba-b receptor ligands for the treatment of neurodegenerative diseases |
| 08/09/2001 | WO2000055072A3 Aerosol metering valve |
| 08/09/2001 | WO2000005224A3 Heterocyclic derivatives and their use as integrin inhibitor |
| 08/09/2001 | US20010012896 Crystallization, heating |
| 08/09/2001 | US20010012895 Therapy for hair loss in mammals; drug resistance; nervous system disorders |
| 08/09/2001 | US20010012889 36 human secreted proteins |
| 08/09/2001 | US20010012885 Conjugate consisting of an active substance and a non-exogeneous native protein |
| 08/09/2001 | US20010012845 Adminstering an E-type prostaglandin ligand and a cyclooxygenase-2 enzyme selective inhibitor compound in combination with a carrier to treat inflammation |
| 08/09/2001 | US20010012836 Determining the presence or absence of a mutation in the nucleotide sequence or absence of a mutation in nucleotide sequence encoding the specific polypeptides in the genome of the subject and analyzing for presence of polypeptide |
| 08/09/2001 | US20010012515 Isolated polypeptide |
| 08/09/2001 | DE19953517C1 Verwendung von Treosulfan zur Konditionierung von Patienten vor Knochemarktransplantation oder Blutstammzelltransplantation Use of treosulphan for conditioning of patients before Knochemarktransplantation or blood stem cell transplantation |
| 08/09/2001 | CA2399982A1 G-protein coupled receptors |
| 08/09/2001 | CA2399686A1 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 08/09/2001 | CA2399649A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides |
| 08/09/2001 | CA2399644A1 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides |
| 08/09/2001 | CA2399603A1 Low dose haptenized tumor cell and tumor cell extract immunotherapy |
| 08/09/2001 | CA2399214A1 Novel heterocyclic amide derivatives |
| 08/09/2001 | CA2399083A1 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives |
| 08/09/2001 | CA2399080A1 Humanized anti-ccr2 antibodies and methods of use therefor |
| 08/09/2001 | CA2399032A1 Ligands for fpr class receptors that induce a host immune response to a pathogen or inhibit hiv infection |
| 08/09/2001 | CA2399026A1 Mucin-1 derived antigens and their use in immunotherapy |
| 08/09/2001 | CA2398998A1 Cd40-binding apc-activating molecules |
| 08/09/2001 | CA2398996A1 Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| 08/09/2001 | CA2398754A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| 08/09/2001 | CA2398261A1 Treating allergic and inflammatory conditions |
| 08/09/2001 | CA2398255A1 Bcl-2-like polynucleotides, polypeptides, and antibodies |
| 08/09/2001 | CA2398215A1 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides |
| 08/09/2001 | CA2369076A1 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | CA2369050A1 Methods for preventing or attenuating pathoangiogenic conditions |
| 08/08/2001 | EP1121937A1 Vaccine preparations containing saponins |
| 08/08/2001 | EP1121454A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 08/08/2001 | EP1121449A1 Delivery system for porcine somatotropin |
| 08/08/2001 | EP1121444A2 Protein kinase homologs |
| 08/08/2001 | EP1121439A2 Methods and compositions for inhibiting neoplastic cell growth |
| 08/08/2001 | EP1121433A2 Human ankyrin family protein |
| 08/08/2001 | EP1121430A1 Human isre-binding protein |
| 08/08/2001 | EP1121424A1 A modified polypeptide with reduced immune response |
| 08/08/2001 | EP1121419A1 Tnfr related gene 12 |
| 08/08/2001 | EP1121375A1 High purity composition comprising (7alpha,17alpha)- 17-hydroxy- 7-methyl- 19-nor-17-pregn- 5(10)-en-20-yn-3-one |
| 08/08/2001 | EP1121373A2 Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| 08/08/2001 | EP1121366A1 Prodrugs of phosphorous-containing pharmaceuticals |
| 08/08/2001 | EP1121362A1 Imidazo-benzazepines having cardiovascular, antitumor, antiinfective and antiinflammatory activity |
| 08/08/2001 | EP1121360A1 Il-8 receptor antagonists |
| 08/08/2001 | EP1121359A1 Imidazo-isoquinoline compounds, their compositions and uses |
| 08/08/2001 | EP1121354A1 N-(imidazolylalkyl)substituted cyclic amines as histamine-h 3? agonists or antagonists |
| 08/08/2001 | EP1121353A1 Benzazine derivatives as phosphodiesterase 4 inhibitors |
| 08/08/2001 | EP1121156A2 Polymer conjugates of interferon beta- 1a and their uses |
| 08/08/2001 | EP1121151A1 Anti-inflammatory alpha2, beta1 integrin-related substances or antibodies |
| 08/08/2001 | EP1121150A1 Delta 6 fatty acid desaturase |
| 08/08/2001 | EP1121148A2 Immunostimulant emulsion |
| 08/08/2001 | EP1121147A1 Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects |
| 08/08/2001 | EP1121146A2 Utilization of proteolytic enzymes to influence hyperactive t cells |
| 08/08/2001 | EP1121136A2 Methods of administering adenoviral vectors |
| 08/08/2001 | EP1121115A1 Pufa supplements |
| 08/08/2001 | EP0815133A4 Human stat4 |
| 08/08/2001 | EP0669829B1 Enhancement of xenograft tolerance and porcine cytokines therefor |
| 08/08/2001 | CN1307568A Crystalline efavirenz |
| 08/08/2001 | CN1307561A Novel VLA-4 inhibitor: oMePUPA-V |
| 08/08/2001 | CN1307484A Antibodies against human CD40 |
| 08/08/2001 | CN1307483A Adjuvant and vaccine composition containing monophosphoryl lipid A |
| 08/08/2001 | CN1307037A Polypeptide-human zinc finger protein 14 and polynucleotide for coding said polypeptide |
| 08/08/2001 | CN1307031A Polypeptide-human zinc finger protein 19 and polynucleotide for coding said polypeptide |
| 08/08/2001 | CN1307019A Polypeptide-human zinc finger protein 49 and polynucleotide for coding said polypeptide |
| 08/08/2001 | CN1307017A Polypeptide-human zinc finger protein 46 and polynucleotide for coding said polypeptide |
| 08/08/2001 | CN1307013A Polypeptide-human zinc finger protein 13 and polynucleotide for coding said polypeptide |
| 08/08/2001 | CN1306979A Polypeptide-robosomal protein L20, 16 and polynucleotide for coding said polypeptide |
| 08/08/2001 | CN1306861A Polysaccharide with certain immunological activity and its preparation |
| 08/08/2001 | CN1306860A Composition and preparation of human tumor antigen-mycobacterium heat shock protein tumor vaccine |
| 08/08/2001 | CN1306859A Preparation of antineoplastic immune vaccine |
| 08/08/2001 | CN1306854A Water extracted and alcohol precipitated matter of subprostrate sophora and its application in medicine |
| 08/08/2001 | CN1069309C N-(aminopropyl)-N-phenyl-5,6,7,8-tetrahydronaphtalene-2-carboxamide derivative, preparation and application thereof |
| 08/08/2001 | CN1069199C Placenta peptide oral liquid and its prodn. method |
| 08/08/2001 | CN1069195C Prep. of suspendible composition |
| 08/08/2001 | CN1069194C Combined construction method of concretepouring and grouting for inclined shafts and vertical shafts |
| 08/08/2001 | CN1069193C Prep. of ointments containing tricyclic compound |
| 08/07/2001 | US6271390 Suppression of the IgE-dependent allergic response by benzimidazole analogs |
| 08/07/2001 | US6271374 Stable crystalline (6S)- and (6R)-tetrahydrofolic acid |
| 08/07/2001 | US6271368 Nucleotide sequences coding moduator of cellular activities; for the use in the prevention of plant consumption; viricides |
| 08/07/2001 | US6271261 Chemokine mediated diseases, binding interleukins or beta-receptors and administering to mammals |
| 08/07/2001 | US6271252 Cyclic amino acid derivatives as cell adhesion inhibitors |
| 08/07/2001 | US6271219 Topical formulations comprising skin penetration agents and the use thereof |
| 08/07/2001 | US6271214 Process for the preparation of immunomodulatory polysaccharides from aloe |
| 08/07/2001 | US6271200 Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles |
| 08/07/2001 | US6271030 For modulation of c/ebp beta (transcription factor enhancer-binding gene) expression and for treatment of diseases associated with expression of c/ebp beta |
| 08/07/2001 | US6270994 Smad6 and uses thereof |
| 08/07/2001 | US6270992 Histidine kinase of Staphylococcus aureus |
| 08/07/2001 | US6270989 A homologous recombinant dna construct comprising a targeting sequence, an exogenous regulatory sequence, an exon and an unpaired splice donor site at the 3'end; gene therapy for thrombopoietin, thrombocytopenia, multiple sclerosis |
| 08/07/2001 | US6270778 Relates to genes encoding melanoma antigens recognized by t-cells and their corresponding proteins. |
| 08/07/2001 | US6270776 Recombinant mycobacterial vaccine |
| 08/07/2001 | US6270772 Mhc class ii based molecules that comprise covalently linked beta 1 and alpha 1 domains, and mhc class i based molecules that comprise covalently linked alpha 1 and alpha 2 domains. |
| 08/07/2001 | US6270769 Providing the antigen to which the ctl response is desired and providing an antigen formulation which consists of two or more of a stabilizing detergent, a micelle-forming agent, and an oil; antigen lacking an immunostimulating peptide component |
| 08/07/2001 | US6270766 Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
| 08/07/2001 | US6270765 Therapeutic compounds comprised of anti-Fc receptor antibodies |